journal article·2022-10Open access

N-acetyl-galactosamine modified metal-organic frameworks to inhibit the growth and pulmonary metastasis of liver cancer stem cells through targeted chemotherapy and starvation therapy

Jing Hu, Jun Hu, Wenrui Wu, Yufei Qin, Junjie Fu, Jingwen Zhou, Chao Liu, Jian Yin

Acta Biomaterialia· Volume 151

Abstract

Hepatocellular carcinoma (HCC) is a common high-mortality malignancy which still needs efficient treatments. HCC patients undergoing extrahepatic metastases are mostly with unsatisfactory prognosis. Therefore, specific attention has been paid to extrahepatic HCC metastasis. We integrated Sorafenib (Sor) and glucose oxidase (GOx) into a N-acetyl-galactosamine (GalNAc) modified zeolitic imidazolate framework (ZIF-8), designated as SG@GR-ZIF-8, for targeted bimodal therapies of chemotherapy and starvation therapy against HCC. The hepatic delivery of SG@GR-ZIF was mediated by the specific recognition of GalNAc residues with asialoglycoprotein (ASGPR) on the liver cell surface. Sor is a clinically approved anti-proliferation and anti-angiogenesis drug for advanced HCC treatment. GOx can efficiently induce cell death and disturb malignant progression by suppressing glucose supply of cancer cells, which is highly associated with metabolic rewiring in metastasis. The nano-formulation exhibit significant anti-metastatic HCC activity against C5WN1 cells, a liver cancer stem cell-like cell line with tumorigenicity and pulmonary metastasis activity. In a subcutaneous C5WN1-tumor carrying mouse model, SG@GR-ZIF exhibits potent synergistic anti-tumor activity with a tumor inhibition rate of 89% and a prolonged survival status. The growth and pulmonary metastasis of HCC in an orthotopic mouse model of HCC was remarkably suppressed in SG@GR-ZIF treated group. The therapeutic strategy targeting energy supply combined with first-line treatment holds great promise for the future treatment of metastatic HCC. STATEMENT OF SIGNIFICANCE: SG@GR-ZIF, a N-acetyl-galactosamine modified metal-organic framework carrying Sorafenib and glucose oxidase, was fabricated for treating metastatic hepatocellular carcinoma (HCC). Sorafenib is an anti-proliferation and anti-angiogenesis drug for advanced HCC treatment. Glucose oxidase blocks energy demand in HCC metastasis by depleting glucose. C5WN1 was used for therapeutic evaluations as a liver cancer stem cell-like cell line with tumorigenicity and pulmonary metastasis activity. In subcutaneous C5WN1-tumor bearing mice, SG@GR-ZIF exhibited a tumor inhibition rate of 89% and prolonged survival period. In orthotopic C5WN1-tumor carrying mice, the growth and pulmonary metastasis of hepatocarcinoma was remarkably suppressed by SG@GR-ZIF. Together, this study suggests the great potential of synergistic chemo/starvation therapy mediated by SG@GR-ZIF for treating metastatic HCC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Hepatocellular Carcinoma Treatment and Prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Cancer statistics, 2021
2. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy10.1053/jlts.2003.50147 ↗
3. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization10.1002/lt.20099 ↗
4. Immunotherapies for hepatocellular carcinoma10.1038/s41571-021-00573-2 ↗
5. Surviving at a distance: organ specific metastasis10.1016/j.trecan.2015.07.009 ↗
6. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma10.3748/wjg.v13.i3.414 ↗
7. Clinical features of hepatocellular carcinoma with extrahepatic metastases10.1111/j.1440-1746.2005.03919.x ↗
8. Hepatocellular carcinoma: metastatic disease
9. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors10.1111/j.1478-3231.2008.01864.x ↗
10. Targeting metabolic transformation for cancer therapy10.1038/nrc2817 ↗
11. Regulation of cancer cell metabolism10.1038/nrc2981 ↗
12. Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond10.1002/wsbm.1406 ↗
13. Targeting the supply lines of cancer – a possible strategy for combating the disease?10.21873/anticanres.15055 ↗
14. Nanomedicines for endothelial disorders10.1016/j.nantod.2015.11.009 ↗
15. Advances in nanomedicine for cancer starvation therapy10.7150/thno.38261 ↗
16. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
17. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo10.1038/nbt.4071 ↗
18. An integrated therapeutic delivery system for enhanced treatment of hepatocellular carcinoma10.1002/adfm.201706600 ↗
19. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system10.1038/nature03794 ↗
20. Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy10.1021/acsnano.8b05200 ↗
21. TPGS−galactose-modified polydopamine co-delivery nanoparticles of nitric oxide donor and doxorubicin for targeted chemo− photothermal therapy against drug-resistant hepatocellular carcinoma10.1021/acsami.1c09610 ↗
22. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts10.1016/j.canlet.2012.08.008 ↗
23. Stimuli-responsive liposomes for drug delivery10.1002/wnan.1450 ↗
24. Natural biodegradable polymers based nano-formulations for drug delivery: a review10.1016/j.ijpharm.2019.03.011 ↗
25. Active targeting of gold nanoparticles as cancer therapeutics10.1039/D0CS01121E ↗
26. Metal-organic frameworks for biomedical applications
27. Covalent organic frameworks for biomedical applications10.1002/adhm.202002090 ↗
28. Recent trends in covalent and metal organic frameworks for biomedical applications10.3390/nano8110916 ↗
29. Smart peptide-based supramolecular photodynamic metallo- nanodrugs designed by multicomponent coordination self-assembly10.1021/jacs.8b04912 ↗
30. Covalent organic frameworks as favorable constructs for photodynamic therapy
31. Supramolecular photothermal effects: a promising mechanism for efficient thermal conversion10.1002/anie.201909825 ↗
32. Fabrication of glyco-metal-organic frameworks for targeted interventional photodynamic/chemotherapy for hepatocellular carcinoma through percutaneous transperitoneal puncture10.1002/adfm.201910084 ↗
33. Rational design of metal organic framework nanocarrier-based codelivery system of doxorubicin hydrochloride/verapamil hydrochloride for overcoming multidrug resistance with efficient targeted cancer therapy10.1021/acsami.7b05142 ↗
34. Hepatic binding protein: the galactose- specific receptor of mammalian hepatocytes10.1002/hep.1840030520 ↗
35. The galactose-specific recognition system of mammalian liver: the route of ligand internalization in rat hepatocytes10.1016/0092-8674(80)90116-6 ↗
36. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics10.1089/nat.2018.0736 ↗
37. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/510.1158/0008-5472.CAN-06-1377 ↗
38. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo10.1158/1535-7163.MCT-12-0093 ↗
39. Production of large amounts of hydrogen peroxide by human tumor cells
40. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis10.1515/BC.2006.049 ↗
41. Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis10.1038/s41388-022-02246-5 ↗
42. Precise and reversible protein-microtubule-like structure with helicity driven by dual supramolecular interactions10.1021/jacs.5b11733 ↗
43. Fluorogenic probing of specific recognitions between sugar ligands and glycoprotein receptors on cancer cells by an economic graphene nanocomposite10.1002/adma.201300187 ↗
44. VEGF as a key mediator of angiogenesis in cancer10.1159/000088478 ↗
45. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model10.3727/000000006783981260 ↗
46. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer10.3390/cells10071715 ↗